Scholarlink

Background <p>Radiotherapy plays a&#xa0;central role in the treatment of cancer patients, with increasing significance in the management of oligometastatic disease. Stereotactic radiotherapy has established itself as an effective and safe treatment modality for intra- and extracranial metastases. It is characterized by high spatial precision, excellent tumor control rates, and a&#xa0;favorable risk profile.</p> Objective <p>This article explores the application of stereotactic radiotherapy for treating patients with oligometastatic disease and discusses the requirements related to target volume definition, dose, treatment delivery, and imaging.</p> Materials and methods <p>Various stereotactic techniques, including stereotactic radiosurgery and stereotactic body radiotherapy, are reviewed. The article particularly focuses on treatment planning and delivery, including the role of various imaging modalities.</p> Results <p>Both intracranial and extracranial stereotactic radiotherapy play a&#xa0;central role in the treatment of oligometastatic tumors. Studies such as the SABR-COMET trial have demonstrated the benefit and safety of stereotactic radiotherapy, thus paving the way for further treatment optimization. Successful implementation of stereotactic radiotherapy relies on meeting a&#xa0;wide range of technical and procedural requirements, as defined by relevant professional societies. Additionally, imaging techniques such as computed tomography, magnetic resonance imaging, and positron emission tomography are crucial for staging, target volume definition, and treatment response assessment.</p> Conclusion <p>Stereotactic radiotherapy has become a&#xa0;cornerstone in the treatment of patients with oligometastatic disease. Despite promising results, further challenges remain. Key areas include the integration of stereotactic radiotherapy into multimodal treatment strategies with the aim of maximizing synergistic effects as well as refinement of patient selection.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Oligometastasierung und Stereotaxie

  • 期刊论文

  • 发表日期：

    2025年5月14日

查看全文
  • Felix Ehret,
  • Stefanie Corradini,
  • Ulf Lützen

摘要

Background

Radiotherapy plays a central role in the treatment of cancer patients, with increasing significance in the management of oligometastatic disease. Stereotactic radiotherapy has established itself as an effective and safe treatment modality for intra- and extracranial metastases. It is characterized by high spatial precision, excellent tumor control rates, and a favorable risk profile.

Objective

This article explores the application of stereotactic radiotherapy for treating patients with oligometastatic disease and discusses the requirements related to target volume definition, dose, treatment delivery, and imaging.

Materials and methods

Various stereotactic techniques, including stereotactic radiosurgery and stereotactic body radiotherapy, are reviewed. The article particularly focuses on treatment planning and delivery, including the role of various imaging modalities.

Results

Both intracranial and extracranial stereotactic radiotherapy play a central role in the treatment of oligometastatic tumors. Studies such as the SABR-COMET trial have demonstrated the benefit and safety of stereotactic radiotherapy, thus paving the way for further treatment optimization. Successful implementation of stereotactic radiotherapy relies on meeting a wide range of technical and procedural requirements, as defined by relevant professional societies. Additionally, imaging techniques such as computed tomography, magnetic resonance imaging, and positron emission tomography are crucial for staging, target volume definition, and treatment response assessment.

Conclusion

Stereotactic radiotherapy has become a cornerstone in the treatment of patients with oligometastatic disease. Despite promising results, further challenges remain. Key areas include the integration of stereotactic radiotherapy into multimodal treatment strategies with the aim of maximizing synergistic effects as well as refinement of patient selection.